Two publicly traded companies are coming together to try to make a new breakthrough in treating vascular dementia.

‍What’s happening:‍

• Hemostemix (TSXV: HEM) and Firefly Neuroscience (NASDAQ: AIFF) have launched a new collaboration to leverage Firefly Neuroscience’s Brain Network Analytics technology platform to measure brain activity before and after patients receive Hemostemix’s ACP-01 treatment for vascular dementia
  

By the numbers:‍

• Hemostemix’s new Phase 1 clinical trial will involve up to 100 individual patients
  
• Firefly Neuroscience’s Brain Network Analytics technology will be used to record brain activity at baseline, 3 months after treatment and 6 months after treatment
  

Why it matters:‍

• The collaboration between Hemostemix and Firefly Neuroscience is aiming to unlock new breakthroughs for treating individuals with vascular dementia, which is a challenging condition in which patients experience reduced blood flow to the brain and start to experience a significant cognitive decline
  

Going deeper:‍

• Hemostemix is one of the only publicly traded companies in North America focused on developing novel treatments for vascular dementia
  
• Firefly Neuroscience recently made waves when they became one of the first publicly listed medical technology companies to get accepted into Nvidia’s (NASDAQ: NVDA) Connect Program

‍